文献速递胸部肿瘤放疗姑息放疗与转移瘤

免疫检查点抑制剂相关放射性回忆性肺炎在肺癌中的发生率、危险因素及CT特征

Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
PubMed 文献 · Radiother Oncol · 2021-01-14

该回顾性研究分析了80例既往接受过肺部放疗且使用PD-1/PD-L1抑制剂治疗的晚期肺癌患者,发现放射性回忆性肺炎(RRP)发生率为18.8%,未识别出显著危险因素,但RRP与ICI相关肺炎存在关联(33.3%,p=0.0021),RRP人群中≥3级肺炎发生率为13.3%。

要点

  • 既往肺部放疗后使用ICI的肺癌患者RRP发生率为18.8%。
  • 未发现与RRP显著相关的临床或剂量学危险因素。
  • RRP与ICI相关肺炎相关,33.3%的ICI肺炎病例与RRP相关(p=0.0021)。

核心结论

  • 在既往接受过肺部放疗并使用ICI治疗的肺癌患者中,RRP发生率较高(18.8%)。
  • 未识别出RRP的危险因素,但观察到RRP与ICI相关肺炎存在关联。

研究设计与样本

  • 回顾性分析2014至2019年单中心接受PD-1或PD-L1抑制剂治疗且既往有肺部放疗史的晚期肺癌患者,共纳入80例进行分析。
  • RRP定义为常规分割放疗结束后>6个月或立体定向体部放疗后>1年,照射野内出现的肺部CT改变。

主要发现

  • 放疗结束至RRP的中位时间为450天(范围231-1859天)。
  • 未发现与RRP显著相关的危险因素。
  • ICI相关肺炎与RRP相关,33.3%的ICI肺炎病例与RRP相关(p=0.0021),可同时或序贯发生。
  • RRP人群中≥3级肺炎发生率为13.3%。

关键数值与推荐

  • RRP定义:常规分割放疗结束后>6个月或立体定向体部放疗后>1年,照射野内出现的肺部CT改变。
  • ICI相关肺炎与RRP相关:33.3%(p=0.0021)。
  • RRP人群中≥3级肺炎发生率:13.3%。

临床怎么用

  • 对既往肺部放疗后使用ICI的肺癌患者,应警惕RRP发生,尤其在放疗结束6个月后。
  • RRP与ICI相关肺炎相关,发生RRP时应监测ICI肺炎的发生。

局限性

  • 回顾性单中心研究,样本量有限(80例可评估)。
  • 未识别出RRP的显著危险因素,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiation recall pneumonitis (RRP) is a delayed radiation-induced lung toxicity triggered by systemic agents, typically anticancer drugs. Immune checkpoint inhibitors (ICIs) have recently been identified as potential causal agents of RRP but its real incidence and potential risk factors remain unknown. MATERIALS AND METHODS: Medical records and CTs of patients treated with programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors for advanced lung cancer between 2014 and 2019 at our tertiary center, and who had a previous history of lung irradiation were retrospectively analyzed. We identified RRP as lung CT modifications occurring in the irradiation field >6 months after conventionally fractionated radiotherapy completion and >1 year after stereotactic body radiation therapy. Clinical and dosimetric data were analyzed to identify potential risk factors for RRP. RESULTS: Among 348 patients treated with ICIs, data from 80 eligible patients were analyzed (median age, 69 years [interquartile range, 11]; 45 men). Fifteen patients (18.8%) presented with RRP. Median time between end of radiotherapy and RRP was 450 days (range, 231-1859). No risk factor was significantly associated with RRP. ICI-related pneumonitis was associated with RRP in 33.3% of cases (p = 0.0021), developing either concomitantly or after RRP. Incidence of grade ≥ 3 pneumonitis in the RRP population was 13.3 %. CONCLUSION: We demonstrated a high incidence of RRP (18.8%) in our population of previously irradiated patients treated with ICIs for lung cancer. We identified no risk factors for RRP, but an association was noted between RRP and ICI-related pneumonitis.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cousin F, Desir C, Ben Mustapha S, et al. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer. Radiother Oncol. 2021. PMID: 33453313. doi:10.1016/j.radonc.2021.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。